GlobeNewsWire · CNS · November 12, 2026

Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day

Get the app for more

Explore stock news, insights and company research.